These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 34081930)
21. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160 [TBL] [Abstract][Full Text] [Related]
22. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B Front Immunol; 2022; 13():918613. PubMed ID: 35874752 [TBL] [Abstract][Full Text] [Related]
23. Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis. Chahine J; Alzubi J; Alnajjar H; Ramchand J; Chetrit M; Klein AL Curr Cardiol Rep; 2020 Jun; 22(8):75. PubMed ID: 32607694 [TBL] [Abstract][Full Text] [Related]
24. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report. Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT Per Med; 2024; 21(2):71-78. PubMed ID: 38275171 [TBL] [Abstract][Full Text] [Related]
25. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease. Haroche J; Abla O Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774 [TBL] [Abstract][Full Text] [Related]
26. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement]. Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636 [TBL] [Abstract][Full Text] [Related]
32. Erdheim Chester disease in a patient with Burkitt lymphoma: a case report and review of literature. Sakr HI; Buckley K; Baiocchi R; Zhao WJ; Hemminger JA Diagn Pathol; 2018 Nov; 13(1):94. PubMed ID: 30474563 [TBL] [Abstract][Full Text] [Related]
34. Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF Mirmomen SM; Sirajuddin A; Nikpanah M; Symons R; Paschall AK; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA Eur Radiol; 2018 Nov; 28(11):4635-4642. PubMed ID: 29736852 [TBL] [Abstract][Full Text] [Related]
35. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging. Gray JCR; Kim J; Digianvittorio M; Feeley NK; Scheel PJ; Siegelman SS; Fishman EK; Rowe SP J Natl Compr Canc Netw; 2020 Jun; 18(6):650-655. PubMed ID: 32502983 [TBL] [Abstract][Full Text] [Related]
36. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances. Haroun F; Millado K; Tabbara I Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613 [TBL] [Abstract][Full Text] [Related]
37. Vemurafenib as first-line therapy in Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352 [TBL] [Abstract][Full Text] [Related]
38. Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations. Prabhakaran N; Jour G; Balar A; Ward N Acta Haematol; 2023; 146(3):245-251. PubMed ID: 36754028 [TBL] [Abstract][Full Text] [Related]
39. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Goyal G; Heaney ML; Collin M; Cohen-Aubart F; Vaglio A; Durham BH; Hershkovitz-Rokah O; Girschikofsky M; Jacobsen ED; Toyama K; Goodman AM; Hendrie P; Cao XX; Estrada-Veras JI; Shpilberg O; Abdo A; Kurokawa M; Dagna L; McClain KL; Mazor RD; Picarsic J; Janku F; Go RS; Haroche J; Diamond EL Blood; 2020 May; 135(22):1929-1945. PubMed ID: 32187362 [TBL] [Abstract][Full Text] [Related]
40. Case report of a patient with Erdheim-Chester disease presenting with neuro-endocrine symptoms and negative for BRAF mutation. Lu L; Zhou J; Yan X; Jin R; Deng S; Lu W; Chen D Medicine (Baltimore); 2023 May; 102(20):e33846. PubMed ID: 37335698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]